Table 4.
Comparison of adverse events between OSAHS and non-OSAHS patients during anticoagulation (n (%))
| Events | OSAHS (n = 32) | Non-OSAHS (n = 65) | Total (n = 97) | P |
|---|---|---|---|---|
| Bleeding | 0 | 3 (4.62) | 3 (3.09) | 0.118 |
| PE aggravation | 0 | 0 | 0 | - |
| Heart failure* | 1 (3.13) | 1 (1.54) | 2 (2.06) | 0.616 |
| Death | 1 (3.13) | 0 | 1 (1.03) | 0.135 |
| Total incidence | 2 (6.25) | 4 (6.15) | 6 (6.19) | 0.985 |
| Silent residual† | 2 (6.25) | 2 (3.08) | 4 (4.12) | 0.473 |
*Patients hospitalized due to heart failure or pulmonary hypertension; †Confirmed residual embolism with no clinical manifestation. OSAHS: Obstructive sleep apnea hypopnea syndrome; PE: Pulmonary embolism.